Biogen
Combative US FDA panel votes against Biogen Alzheimer's treatment drug
Biogen seeks US approval for potential Alzheimer's drug, stock jumps
Roche eyes quick FDA approval of risdiplam for spinal muscular atrophy
Biogen shares plummet 25% after company ends Alzheimer's trials